{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:45:05Z","timestamp":1790419505310,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.pcad.2016.08.006","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T01:19:17Z","timestamp":1472174357000},"page":"97-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Diagnosis and treatment of high density lipoprotein deficiency"],"prefix":"10.1016","volume":"59","author":[{"given":"Ernst J.","family":"Schaefer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimjai","family":"Anthanont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret R.","family":"Diffenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Polisecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bela F.","family":"Asztalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2016.08.006_bb0005","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.08.006_bb0010","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"29","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.08.006_rf0015","first-page":"S0735","article-title":"2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk","author":"Lloyd-Jones","year":"2016","journal-title":"JACC"},{"key":"10.1016\/j.pcad.2016.08.006_rf0020","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus. ACCORD study group","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.08.006_bb0020","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.08.006_bb0025","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","article-title":"Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL\/High Triglycerides and Impact on Global Health Outcomes)","volume":"62","author":"Guyton","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0030","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"JELIS investigators effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2016.08.006_bb0035","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI107332","article-title":"Hyperlipidemia in coronary heart disease. II. Genetic analyses of lipid levels in 176 families and delineation of a new inheroited disorder, combined hyperlipidemia","volume":"52","author":"Goldstein","year":"1973","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2016.08.006_bb0040","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/01.CIR.85.6.2025","article-title":"Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease","volume":"85","author":"Genest","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.08.006_bb0045","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/01.ATV.13.12.1728","article-title":"Familial hypoalphalipoproteinemia in premature coronary artery disease","volume":"13","author":"Genest","year":"1993","journal-title":"Arterioscler Thromb"},{"issue":"8086","key":"10.1016\/j.pcad.2016.08.006_bb0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0140-6736(78)91863-9","article-title":"Plasma-triglycerides in regulation of H.D.L.-cholesterol levels","volume":"2","author":"Schaefer","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.08.006_bb0055","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1172\/JCI115028","article-title":"Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia","volume":"87","author":"Brinton","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2016.08.006_bb0060","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0022-2275(20)39181-1","article-title":"Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study","volume":"35","author":"Schaefer","year":"1994","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2016.08.006_bb0065","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/diacare.26.5.1513","article-title":"Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"26","author":"Robins","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcad.2016.08.006_bb0070","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MOL.0b013e3283468061","article-title":"Metabolic and functional relevance of HDL subspecies","volume":"22","author":"Asztalos","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.08.006_bb0080","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2016.08.006_bb0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jacl.2008.06.002","article-title":"Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein-deficiency states","volume":"2","author":"Santos","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MOL.0b013e32833c1ef6","article-title":"Marked HDL deficiency and premature coronary heart disease","volume":"21","author":"Schaefer","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0095","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacl.2010.05.001","article-title":"Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature","volume":"4","author":"Al-Sarraf","year":"2010","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0100","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.08.006_bb0105","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1172\/JCI114997","article-title":"A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities","volume":"87","author":"Funke","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pcad.2016.08.006_bb0110","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1161\/01.ATV.15.11.1866","article-title":"A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary heart disease","volume":"15","author":"Takata","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacl.2012.10.011","article-title":"HDL deficiency due to a new insertion mutation (ApoA-INashua) and review of the literature","volume":"7","author":"Lee","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0120","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2014.05.935","article-title":"A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production","volume":"235","author":"Anthanont","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2016.08.006_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003063","article-title":"Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach","volume":"8","author":"Haase","year":"2012","journal-title":"PLoS Genet"},{"key":"10.1016\/j.pcad.2016.08.006_bb0130","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1073\/pnas.89.16.7389","article-title":"Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis","volume":"89","author":"Soutar","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pcad.2016.08.006_bb0135","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jmb.2015.10.029","article-title":"Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A-I: what makes the protein amyloidogenic?","volume":"428","author":"Das","year":"2016","journal-title":"J Mol Biol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0140","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jacl.2011.07.002","article-title":"Homozygous lecithin:cholesterol acyltransferase (LCAT) deficiency due to a new loss of function mutation and review of the literature","volume":"5","author":"Roshan","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0145","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jacl.2015.12.007","article-title":"Familial lecithin:cholesterol acyltransferase deficiency: first-in-human treatment with enzyme replacement","volume":"10","author":"Shamburek","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacl.2013.11.005","article-title":"A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy","volume":"8","author":"Dimick","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0155","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1194\/jlr.M400152-JLR200","article-title":"Polymorphisms in the gene encoding lipoprotein lipase in men with low HDL-C and coronary heart disease: the Veterans Affairs HDL Intervention Trial","volume":"45","author":"Brousseau","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2016.08.006_bb0160","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0021-9150(00)00722-X","article-title":"Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease","volume":"154","author":"Brousseau","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2016.08.006_bb0165","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/01.ATV.0000024566.57589.2E","article-title":"Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial","volume":"22","author":"Brousseau","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0170","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1194\/jlr.P008268","article-title":"Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease","volume":"51","author":"Peloso","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pcad.2016.08.006_bb0175","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1126\/science.1099870","article-title":"Multiple rare alleles contribute to low plasma levels of HDL cholesterol","volume":"305","author":"Cohen","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pcad.2016.08.006_bb0180","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/ATVBAHA.107.153858","article-title":"Genetic variation in ABCA1 predicts ischemic heart disease in the general population","volume":"28","author":"Frikke-Schmidt","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pcad.2016.08.006_bb0185","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","article-title":"Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease","volume":"299","author":"Frikke-Schmidt","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.08.006_bb0190","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jalz.2015.04.006","article-title":"Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease","volume":"11","author":"Nordestgaard","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.pcad.2016.08.006_bb0195","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.atherosclerosis.2014.04.030","article-title":"ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment","volume":"235","author":"Akao","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pcad.2016.08.006_bb0200","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T19:10:15Z","timestamp":1617649815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062016300871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0033062016300871"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2016.08.006","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and treatment of high density lipoprotein deficiency","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2016.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}